Printer Friendly

Indivior's RBP-6000 recommended by US FDA Advisory Committees for opioid use disorder.

M2 PHARMA-November 1, 2017-Indivior's RBP-6000 recommended by US FDA Advisory Committees for opioid use disorder

(C)2017 M2 COMMUNICATIONS

Pharmaceutical company Indivior PLC (LON:INDV) said on Tuesday that the US Food and Drug Administration (FDA) Advisory Committees has recommended the approval of RBP-6000 for the treatment of opioid use disorder (OUD).

The US FDA Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 18 to one to recommend approval of RBP-6000 for the treatment of opioid use disorder (OUD).

Additionally, the FDA will consider the Advisory Committees' non-binding recommendation in its review of the New Drug Application for the company's RBP-6000 based on the company's Phase 3 study. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 30 November 2017.

In conjunction, the company's Phase 3 study met its primary efficacy endpoint, with both RBP-6000 dosage regimens demonstrating abstinence rates that were significantly higher versus placebo (300 mg/300 mg: 41.3%; 300 mg/100 mg: 42.7%; placebo: 5.0%, p

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 1, 2017
Words:184
Previous Article:AZTherapies names Karen Reeves, MD as president & CMO.
Next Article:US Food and Drug Administration approves new dosing for Janssen Pharmaceuticals' Xarelto.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters